Clinical Trial

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Study acronym: Serpentine
Recruiting
View on ClinicalTrials.gov →
Summary
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-11-11; most recent amendment 2025-04-29.
Trial Details
NCT Number NCT05621837
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer, Squamous Cell Carcinoma of Head and Neck, Small Cell Carcinoma, NSCLC
Enrollment 1,000 participants
Start Date 2022-03-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-02